Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis

Table 1 Comparison of cumulative survival rates of 200 patients with endometrial cancer based on clinical characteristics

Clinical features	n	Cumulative survival rate (%)	χ2 value	P value
Age (yr)
< 50	84	97.4	5.897	0.002
≥ 50	116	81.5
Non-menopausal	81	96.8	6.793	0.008
Menopausal	119	87.5
Pregnancy history
Yes	155	90.4	0.634	0.269
None	45	100.0
Comorbidities
Polycystic ovary syndrome
Yes	33	100.0	0.310	0.454
None	168	90.6
High blood pressure
Yes	81	88.1	0.600	0.358
None	119	92.1
Obesity
Post-operative adjuvant radiotherapy	79	85.7	1.062	0.280
	121	92.1
Post-operative medroxyprogesterone acetate treatment	72	85.7	0.673	0.195
	128	80.0
Co-Medroxyprogesterone Acetate	61	96.6	4.552	0.047
Not combined with medroxyprogesterone acetate	139	81.0
Type of pathology
Adenocarcinoma	144	95.6
Adenosquamous carcinoma	10	37.5	32.321	< 0.001
Non-adenocarcinoma Typing	7	77.8

Table 2 Assignment of factors influencing prognosis at the early-stage high-risk endometrial cancer

Factors	Assignment
Age	< 50 yr = 0, ≥ 50 yr = 1
Menopause	Not menopausal = 0, Menopausal = 1

Postoperative adjuvant therapy combined medroxyprogesterone acetate = 0, uncombined medroxyprogesterone acetate = 1 pathological type adenocarcinoma = 0, non-adenocarcinoma = 1, adenosquamous carcinoma = 2; molecular typing DNA polymerase gene (POLE) mutation = 0, microsatellite highly unstable type (MSI-H) type = 1, low copy type = 2, high copy type = 3; vascular infiltration None = 0, Yes = 1.

Table 3 Factors influencing the prognosis of patients with early-stage high-risk endometrial cancer

Factors	Assignment
Lymph node metastasis	N0 = 0, N1 = 1, N2 = 2, N3 = 3
Myofilament infiltration	< 1/2 = 0, ≥ 1/2 = 1